AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Cytarabine in induction
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Hydrocortisone in induction
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Idarubicin in induction-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Fludarabine in induction-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Ara-C in induction-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: G-CSF in induction-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone in consolidation-1
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Vincristrine in consolidation-1
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Metotrexato in consolidation-1
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: PEG-ASP in consolidation-1
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone in consolidation-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: ARA-C in consolidation-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: PEG-ASP in consolidation-2
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone in consolidation-3
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Vincristine in consolidation-3
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: Metotrexato in consolidation-3
Study NCT01540812 — intervention group
Intervention type: DRUG
Intervention: PEG-ASP in consolidation-3
Study NCT01540812 — intervention group
Intervention type: PROCEDURE
Intervention: allogeneic HSCT
Study NCT01540812 — intervention group
Intervention type: PROCEDURE
Intervention: Allo HSCT with reduced-intensity conditioning
Study NCT01493999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel reloading
Description: Up to three times 600 mg clopidogrel
Study NCT01493999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 60 mg prasugrel in patients with HPR
Study NCT01825317 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroAD
Description: synchronized TMS+COGNITIVE TRAINING
Study NCT01825317 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
Study NCT03002922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Sunscreen formula Y65-158
Study NCT02725008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02725008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02725008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
Study NCT01652859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Study NCT01652859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for aflibercept)
Description: Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously
Study NCT00519285 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone or Prednisolone
Description: Marketed formulation~5 mg twice daily PO from day 1 continuously
Study NCT03443011 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose CT without intravenous contrast
Description: participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
Study NCT01222078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: otelixizumab
Description: Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
Study NCT03447574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ethanol dilution
Description: Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
Study NCT03447574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ethanol dilution
Description: Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
Study NCT01438515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600mg po once daily x 7 days
Study NCT01438515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100mg po twice daily x 7 days
Study NCT01438515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2% mupirocin ointment
Description: \~ 1cm applied to the anterior nares twice daily for 7 days
Study NCT01438515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% mupirocin ointment
Description: \~ 1cm applied to the anterior nares twice daily for 7 days
Study NCT00926640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 6 cycles 80 mg/m2 IV daily X3 beginning day 2.
Study NCT01438515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4% chlorhexidine gluconate
Description: Daily full body wash (including hair) for 7 days
Study NCT01438515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Description: Daily full body wash (including hair) for 7 days
Study NCT02175745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoro-dihydroxyphenylalanine
Description: Administered intravenously (IV)
Study NCT02175745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Description: Component of an 18F-FDOPA PET/CT or PET/MRI scan
Study NCT02175745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Description: Component of an 18F-FDOPA PET/CT
Study NCT02175745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Description: Component of an 18F-FDOPA PET/MRI
Study NCT00865241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Description: A: Experimental Subjects received Alpharma formulated products under fasting conditions
Study NCT00865241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Study NCT04774276 — intervention group
Intervention type: OTHER
Intervention: cardiac rehabilitation protocol without occupational therapist
Description: cardiac rehabilitation protocol without occupational therapist will be performed (usual practice before January 2021).
Study NCT04774276 — intervention group
Intervention type: OTHER
Intervention: cardiac rehabilitation protocol with occupational therapist
Description: This intervention (occupational therapist) have been added since 2021 for all patients who need a cardiac rehabilitation protocol.~Occupational therapy is scheduled with sessions 3 times a week for 1 month.
Study NCT01968512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
Study NCT01968512 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Same character of Transcranial Direct Current Stimulation but without current
Study NCT04659902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated
Study NCT04659902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein form
Description: Protein form and absence or presence of calcium manipulated
Study NCT03541434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete Blood Count
Description: White blood cell subgroups count
Study NCT03541434 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tympanometry
Description: Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
Study NCT03541434 — intervention group
Intervention type: PROCEDURE
Intervention: Tonsillectomy and/or adenoidectomy
Description: Excision of palatine and/or pharyngeal tonsils.
Study NCT02095405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring.
Study NCT02095405 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring.
Study NCT03943823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal cream
Description: Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
Study NCT03943823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimo-San vaginal gel
Description: Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
Study NCT04812405 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trios4
Description: Examination of occlusal surfaces with 3D scanner and optical criteria
Study NCT02622087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Session-Treatment
Description: There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
Study NCT02254122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR
Study NCT02254122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02254122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respimat®
Study NCT02254122 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Respimat®
Study NCT00201617 — intervention group
Intervention type: DEVICE
Intervention: Bone-anchored hearing aid
Study NCT00841308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision to start and titrate drug treatment based only on home blood pressure monitoring
Description: Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm).
Study NCT00853879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid, Vitamin B6, Vitamin B12
Description: Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate.
Study NCT00853879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B6, B12, L-methylfolate
Description: Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
Study NCT00853879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B6, B12, Placebo
Description: Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo
Study NCT04436705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR) technique
Description: The PMR technique utilized in this study was based on the original technique designed by Jacobson (1938) and subsequently modified by Bernstein and Borkovec (1973). The PMR technique involves tensing the individual muscle groups for about 5 seconds for each muscle. Then, allowing them to relax for about 10 seconds, and notice how the muscle feels when it is relaxed in contrast to how it felt when it was tensed. The technique is accompanied by breathing exercises in order to feel the sense of relaxation. In this study, the PMR technique refers to tensing and relaxing the muscles from the forehead to the feet one by one, including the eleven muscle groups (right arm, left arm, forehead, jaw and neck, back and shoulders, stomach, thighs, right calf, left calf, right foot and left foot). The total procedure takes around 20 minutes.
Study NCT02253732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 months exercise intervention program
Description: 3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength \& aerobic exercises
Study NCT00387049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Program for Smoking Cessation
Study NCT00387049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anxiety Sensitivity Program for Smoking Cessation
Study NCT01991899 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Bio-Manguinhos
Description: 1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
Study NCT01991899 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR GlaxoSmithKline
Description: 390 children will receive 0,5 ml MMR GlaxoSmithKline
Study NCT02423668 — intervention group
Intervention type: PROCEDURE
Intervention: 50% Partial adjustment
Description: Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
Study NCT02423668 — intervention group
Intervention type: PROCEDURE
Intervention: No adjustment
Description: IOL power selection for the second eye irrespective of first eye prediction error
Study NCT02423668 — intervention group
Intervention type: PROCEDURE
Intervention: Full adjustment
Description: Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
Study NCT04484844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOKUYAMA SHIELD FORCE PLUS
Description: Self-reinforcing (SR) monomer technology
Study NCT04484844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride 5% Dental Varnish
Description: 5% NaF
Study NCT02204358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow stem cells
Description: Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits.
Study NCT06730178 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation training
Description: The training tapes used were meditation relaxation training tapes translated form Jacobson progressive relaxation technique with copyrights. The tapes were recorded by a male therapist. Participants were instructed to perform the treatment in the evening, preferably just before bedtime, total time was 15 minutes.
Study NCT01442727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium selenite
Description: 200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
Study NCT01442727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
Study NCT00417638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular cooling by the Celsius Control System
Study NCT00417638 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Study NCT01725360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
Study NCT02364154 — intervention group
Intervention type: OTHER
Intervention: Control group-Blood sampling
Description: Determine the metabolic phenotype of blood plasma by NMR spectroscopy
Study NCT02364154 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: determine amount and type of free circulating miRNA in blood plasma
Study NCT00919542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
Study NCT00919542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: prednisolone 40mg daily then reducing regimen over 16 weeks
Study NCT02634983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QVA149
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
Study NCT02634983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
Study NCT02634983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT03728998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raise (PLR)
Description: A PLR will simulate an autotransfusion of 250-300 cc.~* 1. Starting in semi-succumbed position (45 degree head-up)~* 2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive.
Study NCT03728998 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clearsight non-invasive hemodynamic monitoring system
Description: 3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
Study NCT04008264 — intervention group
Intervention type: DRUG
Intervention: Scopolamine Patch (Transderm V)
Description: During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
Study NCT02741258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepitel Film
Description: Placement of Mepitel Film to prevent skin toxicity
Study NCT03900221 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention